Listen to #TeamWWSEF Gurnoor Kaur explain the project #SynaptiQ, which lead to this year's work, #Eigenpulse, as well as explaining the value of #Sciencefairs @ysc_sjc www.cbc.ca/player/play/...
Kitchener teen creates device that could help treat hospital delirium
Gurnoor Kaur, a Grade 11 student from Cameron Heights Collegiate Institute in Kitchener, has created a device that aims to help spot and treat hospital-induced delirium - a sudden state of confusion o...
www.cbc.ca
May 23, 2026 at 10:28 PM
Listen to #TeamWWSEF Gurnoor Kaur explain the project #SynaptiQ, which lead to this year's work, #Eigenpulse, as well as explaining the value of #Sciencefairs @ysc_sjc www.cbc.ca/player/play/...
Congratulations to Gurnoor Kaur, #TeamWWSEF CWSF 2026 finalist, and national winner of Ingenious+ from @canadianinnovationspace ingeniousplus.ca/submission/s...
SynaptiQ: An AI-powered platform for the prediction and prevention of hospital-induced delirium - Ingenious+
ingeniousplus.ca
May 13, 2026 at 1:27 AM
Congratulations to Gurnoor Kaur, #TeamWWSEF CWSF 2026 finalist, and national winner of Ingenious+ from @canadianinnovationspace ingeniousplus.ca/submission/s...
Feed: "energynews.pro"
By: energynews on Monday, December 1, 2025
By: energynews on Monday, December 1, 2025
Greencells to migrate 3 GW of solar projects to 3E’s platform
Greencells will transfer its entire solar and storage portfolio to 3E’s SynaptiQ platform over a three-year partnership.
energynews.pro
December 1, 2025 at 10:47 PM
Feed: "energynews.pro"
By: energynews on Monday, December 1, 2025
By: energynews on Monday, December 1, 2025
Falls ihr mal wirklich qualifiziertes Personal braucht synaptiqmatch.com/
SynaptIQ Match: Dein Netzwerk für Hochbegabte!
Verbinde dich mit außergewöhnlichen Talenten oder finde neue Karrieremöglichkeiten – SynaptIQ Match bringt Hochbegabte, Kunde und Recruiter zusammen. 🚀 #Hochbegabte #Karriere #Netzwerk“Falls du besondere Themen oder Hashtags bevorzugst, kann ich die Texte weiter anpassen. 😊
synaptiqmatch.com
March 27, 2025 at 12:00 AM
Falls ihr mal wirklich qualifiziertes Personal braucht synaptiqmatch.com/
Synaptiq Therapeutics Emerges Following Acquisition of SYN-001 Program Focused on Pediatric Neuropsychiatric Treatment#USA#Philadelphia#SYN-001#Synaptiq_Therapeutics#Nobias_Therapeutics
Synaptiq Therapeutics Emerges Following Acquisition of SYN-001 Program Focused on Pediatric Neuropsychiatric Treatment
Synaptiq Therapeutics has launched with hopes of advancing SYN-001 for pediatric neuropsychiatric symptoms, following its acquisition from Nobias Therapeutics.
third-news.com
July 23, 2026 at 1:16 PM
Synaptiq Therapeutics Emerges Following Acquisition of SYN-001 Program Focused on Pediatric Neuropsychiatric Treatment#USA#Philadelphia#SYN-001#Synaptiq_Therapeutics#Nobias_Therapeutics
Synaptiq Therapeutics Launches to Advance Rare Disease Treatment with SYN-001#USA#Philadelphia#SYN-001#Synaptiq_Therapeutics #22q11DS
Synaptiq Therapeutics Launches to Advance Rare Disease Treatment with SYN-001
Synaptiq Therapeutics is set to advance SYN-001, a novel therapy for 22q11.2 Deletion Syndrome, with a Phase IIb trial planned for evaluation.
third-news.com
July 23, 2026 at 1:15 PM
Synaptiq Therapeutics Launches to Advance Rare Disease Treatment with SYN-001#USA#Philadelphia#SYN-001#Synaptiq_Therapeutics #22q11DS
Ça me console...je n'ai pas encore trouvé et à cette heure ci j'évite les triturations et sacs de noeuds synaptiq🫣🤭😊
October 2, 2025 at 8:55 PM
Ça me console...je n'ai pas encore trouvé et à cette heure ci j'évite les triturations et sacs de noeuds synaptiq🫣🤭😊
Iceland-based Synaptiq launches with Nobias’ rare disease drug
https://www.byteseu.com/2224098/
The Iceland-headquartered company has renamed Nobias’ NB-001 programme SYN-001 and plans to test it in a Phase 2b trial for neuropsychiatric symptoms associated with 22q11.2 deletion syndrome, also …
https://www.byteseu.com/2224098/
The Iceland-headquartered company has renamed Nobias’ NB-001 programme SYN-001 and plans to test it in a Phase 2b trial for neuropsychiatric symptoms associated with 22q11.2 deletion syndrome, also …
Iceland-based Synaptiq launches with Nobias' rare disease drug - Bytes Europe
The Iceland-headquartered company has renamed Nobias’ NB-001 programme SYN-001 and plans to test it in a Phase 2b trial for neuropsychiatric symptoms
www.byteseu.com
July 24, 2026 at 3:00 PM
Iceland-based Synaptiq launches with Nobias’ rare disease drug
https://www.byteseu.com/2224098/
The Iceland-headquartered company has renamed Nobias’ NB-001 programme SYN-001 and plans to test it in a Phase 2b trial for neuropsychiatric symptoms associated with 22q11.2 deletion syndrome, also …
https://www.byteseu.com/2224098/
The Iceland-headquartered company has renamed Nobias’ NB-001 programme SYN-001 and plans to test it in a Phase 2b trial for neuropsychiatric symptoms associated with 22q11.2 deletion syndrome, also …
UMBC CSEE Professor Tim Oates explores how LLMs can be a force multiplier in startups, from ideation to marketing to customer acquisition, drawing on lessons learned using AI to scale his own data science company, Synaptiq LLC, in-person 12-1pm Wed. March 4 at UMBC. www.csee.umbc.edu/news-events/...
February 26, 2026 at 2:08 PM
UMBC CSEE Professor Tim Oates explores how LLMs can be a force multiplier in startups, from ideation to marketing to customer acquisition, drawing on lessons learned using AI to scale his own data science company, Synaptiq LLC, in-person 12-1pm Wed. March 4 at UMBC. www.csee.umbc.edu/news-events/...